Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

Share this content:
Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK
Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK

CME

Program Description:

The first-in-class, oral, potent, and selective small-molecule competitive inhibitor of anaplastic lymphoma kinase (ALK), crizotinib, was found to have a durable overall response rate and a median progression-free survival of 8.1 months in patients with ALK-positive non–small-cell lung cancer (NSCLC), according to results of a global phase 2 study presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.

INTENDED AUDIENCE:

Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with Lung Cancer.

Activity Objectives:

After participating in this educational activity, participants should be better able to:

  • Identify patients with non–small-cell lung cancer (NSCLC) who may benefit from targeted treatment with an anaplastic lymphoma kinase (ALK) inhibitor.

  • Evaluate the safety and efficacy of ALK inhibitor for the management of advanced NSCLC.

Click Next to begin reading the activity.

Page 1 of 4

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs